Trevena Inc. (NASDAQ:TRVN)’s share price dropped 4% during trading on Tuesday . The stock traded as low as $6.41 and last traded at $6.41, with a volume of 99,874 shares changing hands. The stock had previously closed at $6.68.

TRVN has been the subject of several recent research reports. FBR & Co reissued a “buy” rating and set a $16.00 price objective on shares of Trevena in a research report on Wednesday, May 4th. Needham & Company LLC reissued a “buy” rating on shares of Trevena in a research report on Tuesday, May 3rd. Brean Capital reissued a “buy” rating on shares of Trevena in a research report on Tuesday, May 3rd. Cowen and Company restated a “buy” rating on shares of Trevena in a report on Tuesday, May 3rd. Finally, Zacks Investment Research upgraded Trevena from a “sell” rating to a “hold” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $14.70.

The company has a 50 day moving average of $6.75 and a 200-day moving average of $7.68. The firm’s market capitalization is $349.83 million.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. Analysts predict that Trevena Inc. will post ($1.29) earnings per share for the current fiscal year.

In other news, CEO Maxine Gowen bought 22,084 shares of the stock in a transaction on Friday, May 27th. The stock was acquired at an average cost of $7.12 per share, for a total transaction of $157,238.08. Following the acquisition, the chief executive officer now owns 279,025 shares of the company’s stock, valued at $1,986,658. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Several large investors have recently modified their holdings of TRVN. Jennison Associates LLC boosted its stake in shares of Trevena by 0.3% in the fourth quarter. Jennison Associates LLC now owns 702,341 shares of the biopharmaceutical company’s stock valued at $7,375,000 after buying an additional 2,341 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Trevena during the fourth quarter valued at $1,929,000. Finally, California State Teachers Retirement System boosted its stake in shares of Trevena by 77.9% in the fourth quarter. California State Teachers Retirement System now owns 103,238 shares of the biopharmaceutical company’s stock valued at $1,084,000 after buying an additional 45,212 shares in the last quarter.

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.